Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.
Mato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D, Miller M, Toth P, Lizotte PM, Nasta S, Goldberg S, Chong E, Schuster S, Pecora AL, Goy A. Mato AR, et al. Among authors: goy a. Cancer. 2012 Jul 15;118(14):3565-70. doi: 10.1002/cncr.26731. Epub 2011 Dec 16. Cancer. 2012. PMID: 22180256 Free article.
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Younes A, et al. Among authors: goy a. Blood. 2012 May 3;119(18):4123-8. doi: 10.1182/blood-2012-01-405456. Epub 2012 Feb 27. Blood. 2012. PMID: 22371887 Free PMC article. Clinical Trial.
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. Younes A, et al. Among authors: goy a. Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Ann Oncol. 2017. PMID: 28379322 Free PMC article. Review.
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
Gerecitano J, Goy A, Wright J, MacGregor-Cortelli B, Neylon E, Gonen M, Esseltine D, Boral A, Schenkein D, Busam K, Teruya-Feldstein J, Sachs D, O'Connor OA. Gerecitano J, et al. Among authors: goy a. Br J Haematol. 2006 Aug;134(4):391-8. doi: 10.1111/j.1365-2141.2006.06201.x. Br J Haematol. 2006. PMID: 16882131 Free article. Clinical Trial.
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL. Fehniger TA, et al. Among authors: goy a. Blood. 2011 Nov 10;118(19):5119-25. doi: 10.1182/blood-2011-07-362475. Epub 2011 Sep 21. Blood. 2011. PMID: 21937701 Free PMC article. Clinical Trial.
Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A, Feldman T, Zielonka T, Singavi A, Gadaletta G, Waksmundzki K, Bhattacharyya P, Chow KF, Yang X, Panush D, Agress H, Rosario M, Howlett C, Pecora A, Goy A. Mato A, et al. Among authors: goy a. Leuk Lymphoma. 2013 Dec;54(12):2606-12. doi: 10.3109/10428194.2013.783909. Epub 2013 May 15. Leuk Lymphoma. 2013. PMID: 23488604
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Romaguera JE, et al. Among authors: goy a. Br J Haematol. 2010 Oct;151(1):47-53. doi: 10.1111/j.1365-2141.2010.08315.x. Epub 2010 Aug 5. Br J Haematol. 2010. PMID: 20735402 Free article. Clinical Trial.
245 results